Drug Design and Discovery in Alzheimer’s Disease

by

Atta-ur-Rahman, Mohammad Iqbal Choudhary

DOI: 10.2174/97816080582281150101
eISBN: 978-1-60805-822-8, 2014
ISBN: 978-1-60805-823-5
ISSN: 1574-0889 (Print)
ISSN: 2212-1064 (Online)



Indexed in: Book Citation Index, Science Edition, BIOSIS Previews, Scopus, EMBASE, EBSCO, Ulrich's Periodicals Directory.

“Frontiers in Drug Design and Discovery” is an Ebook series devoted to publishing the latest and the most important advances in drug d...[view complete introduction]
US $
Buy Personal eBook
165
Order Library eBook
660
Order Printed Copy
*235
Order PDF + Printed Copy (Special Offer)
*317

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Somatostatin Receptor-4 Agonists as Candidates for Treatment of Alzheimer’s Disease

- Pp. 566-597 (32)

Karin E. Sandoval, Kenneth A. Witt, A. Michael Crider and Maria Kontoyianni

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by a progressive loss in memory and cognitive abilities. One of the key pathologic features of AD is the accumulation of beta amyloid (Aβ). Somatostatin has been shown to regulate neuronal neprilysin activity, a key enzyme involved in Aβ catabolism. The actions of somatostatin are mediated through somatostatin receptors 1-5. The somatostatin subtype-4 receptor (sst4) is expressed in key regions of the brain impacted by AD. Thus, sst4 agonists may serve as disease modifying agents (i.e., preventative), enhancing enzymatic activity and decreasing neurotoxic Aβ species within key brain regions of AD patients. This chapter will address the viability of such sst4 agonists within the context of AD therapy, in conjunction with strategies for design, synthesis, and recognition at the macromolecular level.

Purchase Chapter  Book Details

Advertisement


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science